Live Feeds
● LIVE Updated 4h ago · 7 sources tracked

FDA appears to pause controversial speedy review program, complete response letter disclosures

The U.S. Food and Drug Administration has paused its controversial commissioner's priority review voucher program, according to multiple reports citing sources. The program, championed by Commissioner Marty Makary, would have granted vouchers for expedited drug reviews. Reports indicate the decision comes ahead of a Senate vote on the nomination of Dr. Dave Overton. The pause effectively halts a mechanism that could have accelerated approvals for certain drug candidates.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (7)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The FDA has paused its commissioner's priority review voucher program.
  • ✓ The program was championed by Commissioner Marty Makary.
  • ✓ The decision comes ahead of a Senate vote on the nomination of Dr. Dave Overton.
🛡️ Source Corroboration: 7 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Multiple outlets report the FDA has shelved the commissioner's priority review voucher program ahead of a Senate confirmation vote.

Live updates

  1. FDA shelves commissioner's priority review voucher program

    The U.S. Food and Drug Administration has paused its controversial commissioner's priority review voucher program, according to multiple reports citing sources. The program, championed by Commissioner Marty Makary, would have granted vouchers for expedited drug reviews. Reports indicate the decision comes ahead of a Senate vote on the nomination of Dr. Dave Overton. The pause effectively halts a mechanism that could have accelerated approvals for certain drug candidates.

    Why it matters

    The commissioner's voucher program drew criticism for potentially bypassing standard review rigor and creating preferential pathways. Its suspension signals a shift in FDA review policy amid leadership transition scrutiny. The program's fate had been debated since its proposal, with industry and lawmakers questioning its legal basis and fairness.

    What is confirmed

    • The FDA has paused its commissioner's priority review voucher program.
    • The program was championed by Commissioner Marty Makary.
    • The decision comes ahead of a Senate vote on the nomination of Dr. Dave Overton.

    Still unconfirmed

    • The pause is directly caused by political pressure from the Senate vote.

    What to watch next

    • Senate confirmation vote on Dr. Dave Overton
    • Official FDA statement on the program's status
    • Guidance on pending or future voucher applications
    Sources used for this update (7)
    1. www.myasset.com — Sector News & Data
    2. Reuters — EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
    3. Fierce Pharma — FDA appears to pause controversial speedy review program, complete response letter disclosures
    4. pharmaphorum — Are Makary's priority review vouchers about to be canned?
    5. BioSpace — FDA’s commissioner voucher program reportedly shuttered ahead of Senate vote on Overton
    6. RAPS — Recon: FDA shelves commissioner's voucher program; Eli Lilly gets first GLP-1 weight-loss pill approved in China
    7. Endpoints News — FDA’s speedy voucher program is dead: report
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community